BioSpace News Archive

Summit announces that it has entered into an exclusive license and commercialisation agreement granting EuroPharma rights in Latin America to Summit’s precision antibiotic ridinilazole in development for the treatment of CDI.

Dr. Novak will succeed Dr. Tony Coles, who has helped lead the company in the transition from its early phase to a clinical-tage public company. Dr. Coles will remain a senior advisor to CRISPR Therapeutics.

The Company plans to file a PMA submission with the FDA during the first quarter of 2018 to support commercialization of the first POC HIV-Syphilis assay in the U.S.

Daxor Corporation announced the payment of a dividend for 2017.

Catalyst Biosciences today announced the pricing of an underwritten public offering of 1,105,263 shares of its common stock, offered at a price of $9.50 per share to the public.

Avinger announced the Company submitted a new 510(k) application to the FDA for its next generation Pantheris Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of PAD.

Related Beal, prominent real estate developer, owner and operator in Boston, today broke ground on a major new addition to Boston’s expanding life sciences cluster in the Raymond L. Flynn Marine Park and announced its first tenant.

The film was created by Emmy-nominated director Abbey LeVine in collaboration with Boehringer Ingelheim Pharmaceuticals.

In early October, two AIT Bioscience employees, April Pisek and Jessica White, presented at the i3 North American Community Forum in Seattle, Washington at the request of IDBS.

Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option under the existing discovery, development and commercialization agreement between the companies to exclusively license from Immatics a proprietary immunotherapy target for further development and commercialization in oncology.